Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 141NIH 46INDUSTRY 34NETWORK 19OTHER_GOV 1FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia 1

Interventions

Exercise 6pembrolizumab 5enzalutamide 4Docetaxel 4Colonoscopy 4Celecoxib 4sargramostim 3apalutamide 3Prednisone 3Methods 3Leuprolide 3Itraconazole 3Imiquimod 3Granulocyte-Macrophage Colony-Stimulating Factor 3Golytely 3Cryotherapy 3Abiraterone Acetate 32-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3abiraterone 2Yoga 2Topotecan 2Testosterone 2Tablets 2Simvastatin 2Radiosurgery 2Palliative Care 2Midazolam 2Gelatin 2Decision Support Techniques 2Collagenases 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Interventional × Mitoxantrone × Clear all
NCT00100477 2013-09-25

Use of Topotecan in Patients With Refractory Acute Leukemia

VA Office of Research and Development

Phase 2 Completed
10 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡